MARKET

NUVL

NUVL

Nuvalent, Inc.
NASDAQ
102.41
+0.33
+0.32%
Opening 14:36 02/11 EST
OPEN
102.73
PREV CLOSE
102.08
HIGH
106.18
LOW
98.71
VOLUME
264.41K
TURNOVER
--
52 WEEK HIGH
113.02
52 WEEK LOW
55.54
MARKET CAP
7.98B
P/E (TTM)
-19.2659
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NUVL last week (0202-0206)?
Weekly Report · 2d ago
Assessing Nuvalent (NUVL) Valuation As A High P/B And DCF Gap Shape Expectations
Simply Wall St · 3d ago
Cantor Fitzgerald Reaffirms Their Buy Rating on Nuvalent (NUVL)
TipRanks · 5d ago
Nuvalent nimmt am Guggenheim Emerging Outlook: Biotech Summit teil
Reuters · 6d ago
Nuvalent Executives to Join Guggenheim Emerging Outlook Biotech Summit
Reuters · 6d ago
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
PR Newswire · 6d ago
Nuvalent Chief Development Officer Darlene Noci Reports Disposal of Common Shares
Reuters · 02/02 21:31
Weekly Report: what happened at NUVL last week (0126-0130)?
Weekly Report · 02/02 09:16
More
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.

Webull offers Nuvalent Inc stock information, including NASDAQ: NUVL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NUVL stock methods without spending real money on the virtual paper trading platform.